|1.||Golmard, Jean-Louis: 2 articles (04/2014 - 01/2012)|
|2.||Lacut, Karine: 2 articles (04/2014 - 03/2012)|
|3.||Siguret, Virginie: 2 articles (04/2014 - 01/2012)|
|4.||Loriot, Marie-Anne: 2 articles (04/2014 - 01/2012)|
|5.||Moreau, Caroline: 2 articles (04/2014 - 01/2012)|
|6.||Andro, Marion: 2 articles (04/2014 - 03/2012)|
|7.||Roth, B: 2 articles (03/2012 - 12/2005)|
|8.||Becquemont, Laurent: 2 articles (03/2012 - 01/2012)|
|9.||Tortel, M-C: 2 articles (03/2012 - 12/2005)|
|10.||Lechat, P: 2 articles (01/2001 - 11/2000)|
01/01/2001 - "Evaluation of the preventive efficacy against nonfatal thromboembolic events and vascular deaths of the combination of the oral anticoagulant fluindione and aspirin (100 mg) in patients with high-risk atrial fibrillation. "
11/01/2000 - "[Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. "
01/01/2001 - "Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. "
12/01/2003 - "The prevention of the thromboembolic complications of chronic atrial fibrillation remains a therapeutic challenge because they cannot be completely suppressed by vitamin K antagonists with a target international normalized ratio between 2 and 3. Evaluation of the combination at that international normalized ratio level with antiplatelet therapy was the aim of the placebo-controlled double-blind Fluindione Fibrillation Auriculaire, Aspirine et Contraste Spontané (FFAACS) study with fluindione (as anticoagulant) and aspirin (100 mg) in patients with chronic atrial fibrillation at high risk of thromboembolic complications. "
04/01/2015 - "We extracted data for adults (aged ≥18 years) with non-valvular atrial fibrillation who received their first prescription for a vitamin K antagonist (fluindione, warfarin, or acenocoumarol) between Jan 1, 2011, and Nov 30, 2012, and who were either switched to a NOAC (dabigatran or rivaroxaban) or maintained on the vitamin K antagonist. "
02/15/2005 - "A relay treatment with fluindione was initiated on day 5. The left ventricular thrombus outcome was followed for 3 weeks by bi-weekly transthoracic echocardiography. "
09/01/1999 - "Thus, the effectiveness of fluindione for preventing arterial thrombosis is dependent on the nature of the thrombogenic trigger. "
09/01/1999 - "Fluindione inhibited thrombus formation on TF-coated coverslips in a dose-dependent manner by 50% and 80% at INR 1.5 to 2.0 and INR 2.1 to 3.0, respectively (P<0.05). "
09/01/1999 - "Fluindione is very effective in preventing TF- but not collagen-triggered thrombus formation. "
09/01/1999 - "Collagen-induced thrombus formation was not reduced in subjects treated by fluindione. "
|4.||Interstitial Nephritis (Tubulointerstitial Nephritis)
02/01/2009 - "Fluindione-induced immuno-allergic interstitial nephritis."
10/01/2008 - "[Acute interstitial nephritis of fluindione: about three cases]."
12/01/2006 - "A review of the literature revealed a very low incidence of fluindione-induced interstitial nephritis, with variable renal and extra-renal signs. "
12/01/2006 - "We describe here a patient with acute immuno-allergic interstitial nephritis caused by fluindione. "
12/01/2006 - "Acute immuno-allergic interstitial nephritis caused by fluindione."
12/01/2005 - "These manifestations were consistent with the diagnosis of drug-induced hypersensitivity syndrome due to fluindione. "
10/01/2001 - "The authors report herein the first five cases of drug-induced hypersensitivity syndrome due to fluindione. "
11/01/2010 - "Several hypersensitivity reactions affecting various organ systems have been reported in detail in patients taking fluindione, mainly cutaneous, hepatic or renal disorders, often associated with fever. "
12/01/2006 - "Bleeding is the most common side effect of fluindione, whereas hypersensitivity reactions are rare. "
12/01/2003 - "A few rare cases of fluindione-induced hypersensitivity reactions and acute interstitial nephritis, however, have been described."
|1.||Aspirin (Acetylsalicylic Acid)
|7.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|10.||Cytochrome P-450 CYP1A2 (CYP1A2)
|1.||Transplantation (Transplant Recipients)
|2.||Home Nursing (Nursing, Home)